At a glance
- Originator Merck & Co
- Class Antineoplastics
- Mechanism of Action Cholestenone 5-alpha reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acne; Alopecia; Benign prostatic hyperplasia; Hirsutism; Prostate cancer; Seborrhoeic dermatitis
Most Recent Events
- 28 Feb 2000 No-Development-Reported for Acne in USA (PO)
- 28 Feb 2000 No-Development-Reported for Alopecia in USA (PO)
- 28 Feb 2000 No-Development-Reported for Benign prostatic hyperplasia in USA (PO)